Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.
September 15, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $152.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ascendis Pharma. The maintained price target of $152 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100